Table 2.
Myocarditis/pericarditis following SARS-CoV-2 vaccination, SARS-CoV-2 infection, and compared to background risk.
|
SARS-CoV-2 vaccination |
SARS-CoV-2 infectiona | Background (2019)b | |||
|---|---|---|---|---|---|
| BNT162b2 | CoronaVac | ChAdOx1 | |||
| Total events | 67 | 15 | 5 | 157 | 200 |
| Persons | 20,177,008 | 9,900,007 | 2,830,339 | 2,793,430 | 27,397,700 |
| Risk per 100,000 persons (95% CI) | 0.33 (0.26 to 0.42) |
0.15 (0.09 to 0.25) |
0.18 (0.06 to 0.41) |
5.62 (4.78 to 6.57) |
0.04 (0.02 to 0.07) |
| Risk ratioc (95% CI) |
7.91 (4.08 to 15.5) |
3.61 (1.51 to 8.09) |
4.21 (1.20 to 13.7) |
133.8 (76.1 to 286.2) |
Reference |
Abbreviation: CI, confidence interval.
a
Events post SARS-CoV-2 infection were defined as diagnosis within 1–21 days of positive test.
b
Background risk were calculated from the hospital episode database for the year 2019 and Malaysian population as the denominator and standardised to 21 days.
c
Risk ratio was calculated as risk per 100,000 persons for the respective cohort (BNT162b2, CoronaVac, ChAdOx1, and SARS-CoV-2 infection) divided by risk in the population for the year 2019 (background 2019).